| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Agile Therapeutics (OTC:AGRX) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:05 AM.
Here's what investors need to know about the announcement.
Agile Therapeutics missed estimated earnings by -59.0%, reporting an EPS of $-1.46 versus an estimate of $-0.92.
Revenue was down $381 thousand from the same period last year.
Last quarter the company beat on EPS by $0.37 which was followed by a 2.0% drop in the share price the next day.
Here's a look at Agile Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.84 | -3.48 | -7.50 | -11.5 |
| EPS Actual | -1.47 | -3.10 | -7.76 | -9 |
| Revenue Estimate | 5.27M | 4.68M | 3.40M | 3.08M |
| Revenue Actual | 6.66M | 5.50M | 3.81M | 4.00M |
To track all earnings releases for Agile Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AGRX
